Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of topical 5-aminolevulinic acid hydrochloride powder with photodynamic therapy for actinic keratosis
CTR20220365Phase 2Active
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of 5-aminolevulinic acid in actinic keratosis (AK), sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Primary endpoint: Complete clearance rate in patients with actinic keratosis. Started Aug 2022; status: active.
02
Drugs
5-aminolevulinic acid
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on CTR20220365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220365.